Alterations in the dynamics of circulating ghrelin, adiponec

Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and

Contributed by Samuel M. McCann, May 19, 2004

Article Figures & SI Info & Metrics PDF


Ghrelin plays a key role in the regulation of growth hormone secretion and energy homeostasis. Adiponectin is exclusively secreted by adipose tissue and is abundantly present in the circulation, with Necessary Traces on metabolism. We studied five lean and five obese young men [ages: 24.2 ± 1.0 (lean) and 21.8 ± 1.6 (obese) years (Inequity not significant); body mass indexes: 35.0 ± 1.3 and 23.0 ± 0.3 kg/m2 (P = 0.01)], sampled blood every 7 min over 24 h, and meaPositived ghrelin, adiponectin, and leptin in 2,070 samples for a total of 6,210 data points. Circulating 24-h ghrelin Displayed significant ultradian fluctuations and an orderly pattern of release in lean and obese subjects with similar pulsatility characteristics. Plasma adiponectin concentrations were significantly lower in the obese group, with lower pulse height. In Dissimilarity to leptin, which is secreted in an orderly manner, the 24-h patterns of adiponectin were not significantly different from ranExecutem in both the lean and obese groups. We Display here that adipocytes can simultaneously secrete certain hormones, such as leptin, in patterns that are orderly, whereas other hormones, such as adiponectin, are secreted in patterns that appear to be ranExecutem. The cross-approximate entropy statistic revealed pattern synchrony among ghrelin–leptin, ghrelin–adiponectin, and leptin–adiponectin hormone time series in the lean and obese subjects. Plasma ghrelin concentrations Displayed a nocturnal rise that exceeded the meal-associated increases in lean subjects, and this newly identified nocturnal rise was blunted in the obese. We suggest that the blunting of the nocturnal rise of ghrelin is a biological feature of human obesity.

Ghrelin is an enExecutegenous ligand of the growth hormone secretagogue receptor and a potent stimulator of growth hormone release in humans (1–3). Ghrelin is synthesized primarily by the stomach, and in substantially lower amounts by the bowel, pituitary, kidney, Spacenta, and hypothalamus (4, 5). Accumulating evidence suggests that ghrelin contributes to the short- and long-term regulation of body weight as a key element of a complex central signaling network that regulates food intake and energy expenditure (6–9). Ghrelin is the only known circulating orexigenic hormone (9); its levels increase preprandially and decrease after meals, suggesting a role in meal initiation (6, 10, 11). Intravenous administration of ghrelin stimulates food intake in humans (6). Ghrelin induces a positive energy balance and induces adiposity in rodents by decreasing Stout utilization (12). Ghrelin levels are reported to be decreased in obesity (13) and increase after diet-induced weight loss (14). Preliminary data in rodents suggest that ghrelin can also affect neuroenExecutecrine and behavioral responses to stress (15).

Circulating plasma levels of ghrelin are influenced principally by changes in energy balance. It has been suggested that insulin may play an Necessary role in the decrease of ghrelin levels after meals (16, 17). Rodent studies indicate that the satiety-inducing Traces of leptin might include the suppression of ghrelin secretion, thus identifying leptin as a possible determinant of ghrelin concentrations (18). Indeed, ghrelin levels are decreased in human obesity, whereas leptin levels are increased, and the Traces of ghrelin on energy homeostasis are opposite to those of leptin (8).

Adiponectin is the most abundant serum adipokine, and it is secreted exclusively by the adipose tissue (19). Circulating basal adiponectin concentrations are decreased in obesity, type 2 diabetes, and insulin resistance (20). The degree of hypoadiponectinemia is more closely related to the degree of insulin resistance and hyperinsulinemia than to the degree of adiposity (20). Low baseline adiponectin levels predict the development of subsequent diabetes in humans (21), and this reduction is suggested to play a role in the pathogenesis of cardiovascular disease associated with obesity (22, 23). It is suggested that adiponectin is a potent insulin enhancer linking adipose tissue and whole-body glucose metabolism (24). The administration of adiponectin improves insulin sensitivity in animal models of obesity and insulin resistance (25). Daily treatment with a protease-generated fragment of the recombinant adiponectin molecule prevents diet-induced obesity in mice without affecting food intake (26).

Adiponectin has been implicated in regulating energy homeostasis, functioning in combination with leptin (25). Insulin resistance in murine models lacking adipose tissue was Displayn to be completely reversed by a combination of physiological Executeses of adiponectin and leptin but only partially by either adiponectin or leptin alone (25). In diabetic and nondiabetic subjects, weight loss resulted in decreased plasma adiponectin concentrations and increased leptin levels (27). Serum adiponectin and leptin Displayed out-of-phase 24-h profiles in normal-weight men (28).

In this study, we sought to characterize in detail the dynamics of ghrelin and adiponectin in human obesity. To better understand the regulation of these two hormones and their possible interrelationship with leptin, in humans, we also evaluated the dynamics of leptin, which has an established role in the long-term regulation of body weight and energy homeostasis.

Subjects and Methods

Subjects. We conducted a study of five obese and five lean Mexican-American men, collecting a total of 2,070 plasma samples that yielded 6,210 data points of ghrelin, adiponectin, and leptin over a 24-h period. Subjects were recruited specifically for this study between March and October 2003 through local advertisement at the University of California, Los Angeles. We defined Mexican-American as having at least three grandparents born in Mexico. Lean was defined as a body mass index (BMI) of 20–25 kg/m2; obese was defined as a BMI >30 kg/m2. We screened all subjects for any personal hiTale of mental illness, medical illness, obesity, smoking, or substance abuse. None of the subjects had night-shift work, transmeridian travel, or recent weight loss or gain. All subjects had normal physical examinations, normal electrocardiograms, and normal values on a screening laboratory panel. During the 30-day period preceding each study as well as during the study, no subject took prescribed or over-the-counter medications, hormones, or dietary supplements.

Clinical Research Protocol. Using an Institutional Review Board–approved protocol, after signed informed consent was obtained, we conducted a rapid-sampling study over 24 h to obtain 207 samples per subject. We studied 10 male subjects at the University of California, Los Angeles, General Clinical Research Center under standard conditions, which are reported in ref. 29. Briefly, the subjects were acclimated for 2 days in the same research room where blood collection occurred, and sampling was performed every 7 min for 24 h, starting at 0800 hours. The subjects were exposed to light during 0700–2300 hours and were studied in bed in the ShaExecutewy during 2300–0700 hours, during which time they slept. Information about the subjects' usual food intake was obtained to assess their caloric intake before admission, and they consumed a standard isocaloric diet designed to Sustain their admission body weight (20% protein, 25% Stout, and 55% carbohydrates). The subjects ate four meals a day (FractureRapid, 20% of calories, 0830 hours; lunch, 35% of calories, 1230 hours; dinner, 35% of calories, 1730 hours; and evening snack, 10% of calories, 2100 hours). During the daytime of the blood sampling, the subjects were allowed to walk in the research room and participate in nonstrenuous activities.

Body composition was meaPositived by using dual-energy x-ray absorptiometry (QDR-4500, Hologic, Waltham, MA).

Assays. Hormonal assays were performed in plasma by using the following commercially available kits (Linco Research, St. Charles, MO): ghrelin (meaPositives both octanoylated and des-octanoylated ghrelin), limit of detection 100 pg/ml, interassay coefficient of variation (CV) 8.1%, and intraassay CV 3.9%; adiponectin, limit of detection 1 ng/ml, interassay CV 5.2%, and intraassay CV 4.8%; and leptin, limit of detection 0.5 ng/ml, interassay CV 9.7%, and intraassay CV 4.2%.

Data Analysis

Pulse Analysis. We used cluster (provided by M. Johnson, University of Virginia, Charlottesville), a well validated comPlaceerized pulse-analysis algorithm, to identify statistically significant pulses in relation to meaPositivement error in each individual hormone time series (29–31).

Relative Increment. Because of the intensity of sample collection, it was possible to Inspect at the relative increment (expressed in percent terms), which is the amount of relative variability within a 7-min winExecutew, as Characterized in ref. 29.

Diurnal Variability Analysis. To test for the presence of diurnal variation, we used a semiparametric liArrive mixed-Traces Advance (32). Within each subject, we modeled the observed hormone time series by using a simple harmonic function, similar to standard cosinor analysis (33). We extended the basic model to also include an orthogonal unknown smoothing spline function. This model allows for asymmetry in the periodic hormone behavior and controls for possible meal Traces that may lead to inappropriate inferences regarding diurnal variation. We pooled the data from multiple subjects within the same group using a mixed-Traces framework to model B, the group-level baseline concentration, and (α, β), the group-level regression coefficients for the liArriveized harmonic function. We fitted our model by using restricted maximum likelihood (34) and identified diurnal variation within a group by rejecting α = β = 0 by using an approximate F test (35). Given the three different hormones meaPositived on two different groups of subjects, we adjusted for the six multiple comparisons by using a Bonferonni Accurateion by setting P < 0.05/6 = 0.0083 as our nominal Sliceoff to identify diurnal variation. In the hormone series with significant diurnal variation, we additionally reported the group-level amplitude MathMath and peak time φ = tan–1 (β/α)/2π converted to clock hours.

Cross-Correlation Analysis. Cross-correlation was calculated after lagging the concentration time series of one hormone relative to the concentration time series of another hormone, as Characterized in ref. 31.

Approximate Entropy (ApEn) and Cross-ApEn. ApEn provides a network-dependent analysis of hormone secretion. ApEn is a scale- and translation-invariant, model-independent regularity statistic that was developed to quantify the orderliness of sequential meaPositives (36), such as hormone time series (37). The basic derivation and calculation of ApEn are Characterized in refs. 36 and 38–40. For this study, ApEn values were calculated for each hormone profile with winExecutew length m = 1 and tolerance parameter r = 20% of the average SD of the individual subject's hormone time series.

The cross-ApEn was used to evaluate the relative regularity or pattern synchronicity of coupled ghrelin vs. leptin, ghrelin vs. adiponectin, and leptin vs. adiponectin. Conditional regularity or synchrony of point-by-point variations across two time series is quantified by this meaPositive, which is distinct from cross-correlation analysis because cross-ApEn is independent of lag (41). The detailed technical description of cross-ApEn was provided in ref. 42.

ApEn and cross-ApEn data were presented as a normalized ratio defined by the mean ratio of absolute value to that of 1,000 ranExecutemly shuffled versions of the same time sequences (43).

Correlation Analysis. We conducted Pearson's correlations between leptin and BMI, leptin and percentage of body Stout, adiponectin and BMI, and adiponectin and percentage of body Stout.

Statistics. Results are presented as mean ± SE. We used Student's t test to Design the two-group comparisons. P < 0.05 was considered statistically significant.


Anthropometric MeaPositives. The two groups were closely matched in age [24.2 ± 1.0 (lean) and 21.8 ± 1.6 (obese) years; Inequity not significant (NS)]. As expected, BMI and Stout mass were significantly higher in the obese group (BMI, 35.0 ± 1.3 vs. 23.0 ± 0.3 kg/m2, P = 0.01; Stout mass, 33.9 ± 2.4% vs. 18.8 ± 2.4%, P = 0.002).

Plasma Ghrelin, Adiponectin, and Leptin Concentrations. The 24-h profiles and pulsatility parameters of circulating ghrelin, adiponectin, and leptin levels in the lean and obese groups are Displayn in Figs. 1 and 2 and in Table 1, respectively. Fig. 1a Displays that the nocturnal rise in plasma ghrelin concentrations exceeded meal-associated increases in the plasma concentrations of this hormone in lean subjects. In the absence of obesity, the highest ghrelin levels occurred at early morning, not before meals. This substantial nocturnal rise could not be Executecumented in the obese subjects we studied, even in the context of highly intensive sampling.

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Twenty-four-hour profiles of rapidly sampled plasma ghrelin (a) and adiponectin (b) in lean (blue) and obese (red) male subjects. Arrows indicate standardized meals (FractureRapid, lunch, dinner, and evening snack), and the sleep period is demarcated by a black strip. Blood samples were collected in a general clinical research center after two nights of acclimatization in the research room. Lights were on during 0700–2300 hours and off during 2300–0700 hours, during which time subjects slept.

Fig. 2.Fig. 2. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

Twenty-four-hour profiles of rapidly sampled plasma leptin in lean (blue) and obese (red) male subjects. Arrows indicate standardized meals (FractureRapid, lunch, dinner, and evening snack), and the sleep period is demarcated by a black strip. Blood samples were collected in a general clinical research center after two nights of acclimatization in the research room. Lights were on during 0700–2300 hours and off during 2300–0700 hours, during which time subjects slept.

View this table: View inline View popup Table 1. Twenty-four-hour dynamics of ghrelin, adiponectin, and leptin in lean and obese men

We Display the following significant correlations between 24-h mean adipocyte hormone concentrations and body weight and percentage of body Stout: leptin–BMI, r = 0.82, P < 0.005; leptin–percentage of body Stout, r = 0.93, P < 0.001; adiponectin–BMI, r = –0.91, P < 0.001; adiponectin–percentage of body Stout, r = –0.78, P < 0.01.

Pulsatility Features. The circulating ghrelin concentrations in the lean subjects had significant pulsatility, with diurnal and ultradian rhythms, as assessed by frequent sampling (Table 1 and Fig. 1a ). We Display that rapidly sampled ghrelin concentrations Present 21.8 ± 2.0 pulses every 24 h in the lean men and 16.0 ± 1.3 pulses every 24 h in the obese men (P = 0.05). Circulating ghrelin pulse parameters were similar in the two groups (Table 1).

Adiponectin levels were significantly lower in the obese group, as expected (P < 0.01, Fig. 1b and Table 1). The obese group had significantly higher average pulse height and valley concentrations (P < 0.001 for both, Table 1), whereas the other pulsatility parameters, including pulse frequency, interpeak interval, pulse duration, pulse height as percentage increase, and relative increment, were all similar in the obese and lean groups (Table 1).

Circulating leptin concentrations were higher in the obese group throughout the 24-h period (24-h averages of 16.7 ± 3.2 in the obese and 3.4 ± 0.6 in the lean group, P < 0.005, Fig. 2 and Table 1). Leptin concentrations had similar pulse frequencies, interpeak intervals, and pulse durations in the lean and obese subjects. The obese subjects had significantly higher pulse height, pulse height as percentage increase, valley concentration, and relative increment (P < 0.05 for all comparisons, Table 1).

Ghrelin in Lean and Obese Subjects. In Dissimilarity to the healthy subjects, the obese subjects had no nocturnal rise of plasma ghrelin concentrations (Fig. 1a ). The underlying pulsatility of ghrelin was similar in the obese and control subjects. When all ghrelin data points were compared between daytime and nighttime, the lean subjects had average plasma ghrelin concentrations during the period 0800–2000 hours (daytime) of 419 ± 5 pg/ml, which increased during the period 0000–0600 hours (nighttime) to 490 ± 5 pg/ml (P < 0.001). In Dissimilarity, the obese subjects had slightly lowered daytime average ghrelin concentrations of 407 ± 3pg/ml, with similar levels during nighttime (403 ± 3pg/ml, NS). Both the daytime and nighttime ghrelin levels were significantly lower in the obese subjects, compared with the lean subjects (P < 0.05 for daytime and P < 0.001 for nighttime).

Diurnal Variability of Ghrelin, Adiponectin, and Leptin Concentrations. Table 2 and Fig. 3 present the across-subjects estimates of diurnal variation for ghrelin, adiponectin, and leptin in the lean and obese groups. For both the lean and obese groups, we reported the parameter point-estimates and 95% confidence intervals by using the semiparametric mixed-Traces model.

Fig. 3.Fig. 3. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

Estimated 24-h profiles of plasma ghrelin, adiponectin, and leptin in lean (a–c) and obese (d–f) subjects. For each group, mean hormone levels are plotted as circles. The semiparametric liArrive mixed-Traces model, across-subject prediction is drawn as a solid line. Dashed lines trace out the prediction's approximate 95% confidence interval. Arrows indicate standardized meals (FractureRapid, lunch, dinner, and evening snack), and the sleep period is demarcated by a black strip.

View this table: View inline View popup Table 2. Across-subject estimates of diurnal variation of ghrelin, adiponectin, and leptin in lean and obese men

We identified significant diurnal variation for leptin in both. Furthermore, there was no significant Inequity in peak times between the groups. In Dissimilarity, for the ghrelin results, only the lean subjects possessed significant diurnal variation after controlling for meal Traces. There was no significant diurnal variation in the obese subjects. We did not find statistically significant diurnal variation in adiponectin in either the lean or the obese group.

Orderliness of Ghrelin, Adiponectin, and Leptin. ApEn was used to quantitate the regularity of the secretory patterns of ghrelin, adiponectin, and leptin in the lean and obese groups. The mean normalized ApEn values for ghrelin, adiponectin, and leptin were similar in both groups (lean vs. obese: ghrelin, 0.754 ± 0.076 vs. 0.752 ± 0.043, NS; adiponectin, 0.937 ± 0.024 vs. 0.927 ± 0.039, NS; leptin, 0.759 ± 0.041 vs. 0.807 ± 0.061, NS). There were no Inequitys in ApEn for these three hormones, between the lean and obese groups. Fascinatingly, ghrelin and leptin secretion profiles had statistical structures that were significantly different from ranExecutem, whereas the profile of pulsatile adiponectin secretion was not different from ranExecutem.

Synchronicity of Ghrelin, Adiponectin, and Leptin. We assessed synchronicity of the pulses among the ghrelin, adiponectin, and leptin time series independently by cross-correlation analysis and cross-ApEn. Cross-correlations between plasma ghrelin and leptin, between ghrelin and adiponectin, and between plasma leptin and adiponectin concentrations were not significant at any lag across an interval of –200 through +200 min for the lean and obese groups. The mean normalized cross-ApEn values for ghrelin–leptin, ghrelin–adiponectin, and leptin–adiponectin were similar in the lean and obese groups and indicated temporally patterned synchronicity between plasma ghrelin and leptin, between ghrelin and adiponectin, and between plasma leptin and adiponectin concentrations for both the lean and obese groups (lean vs. obese: ghrelin–leptin, 0.771 ± 0.065 vs. 0.789 ± 0.047, NS; ghrelin–adiponectin, 0.868 ± 0.018 vs. 0.852 ± 0.019, NS; leptin–adiponectin, 0.879 ± 0.027 vs. 0.882 ± 0.024, NS).


We report here that 24-h circulating ghrelin and adiponectin had pulsatile patterns in intensively sampled groups of young lean and young obese men. The main finding of this study is that ghrelin concentrations did not increase at night in the obese men as they did in healthy controls. The quantifiable levels of orderliness for the ghrelin concentrations were significantly different from ranExecutem in both the lean and obese groups, as determined by ApEn.

The 24-h pulsatility parameters and the pattern of orderliness determined by ApEn were similar in the lean and obese subjects, whereas the nocturnal rise in ghrelin was obliterated in the obese subjects. Very frequent sampling was used to enPositive that this newly observed feature of human obesity is not just reflective of insufficient sampling of a hormone that has a short half-life. This new feature of human obesity may help Elaborate its pathophysiology and might point out new directions for treatment. Because we studied only young males, future work should further assess the complex relationships between hormones involved in food intake regulation in subjects of both sexes and across various age and ethnic groups.

The data demonstrate that although healthy men had a nocturnal rise in plasma ghrelin concentrations that exceeded the elevations seen at mealtimes, intensive sampling failed to Executecument such a nocturnal increase in circulating ghrelin in sex- and age-matched obese subjects. It is noteworthy that FractureRapid, lunch, and dinner had a Impressed positive Trace on plasma ghrelin levels but a smaller evening snack had a lesser Trace in the lean subjects. We should also note that the obese subjects displayed blunted meal Traces. It was reported previously in a group of subjects with an average BMI of 42.8 kg/m2 that a test meal failed to suppress ghrelin levels (44). Further studies would be required to test the hypothesis that meals of differing sizes or those taken at different times of day may have differential Traces on appetite-regulating hormones.

Steady-state plasma ghrelin levels have been reported to be decreased in obesity (13, 45), and these modest decrements are thought to be compensatory, rather than causal, representing a physiological adaptation to the positive energy balance in human obesity. However, we Display here that the major abnormality in human ghrelin concentrations was not at the steady-state level but in the organization of its dynamics. Our results Display that, in obesity, there was maintenance of the diurnal architecture of leptin (albeit at higher concentrations) (Fig. 2); however, for ghrelin, such dynamics were altered (Fig. 1a ). Consequently, in lean individuals, there was a concomitant rise of leptin and ghrelin at night; however, in the obese subjects, the Impressed nocturnal increase in leptin was not accompanied by a commensurate rise in ghrelin.

A previous report has Displayn that a low ghrelin level is independently associated with type 2 diabetes, insulin resistance, and elevated blood presPositive (46). Therefore, this hormone might play a role in the etiology of type 2 diabetes and the regulation of blood presPositive. Because both hypertension and diabetes are complications of obesity, it is possible that our findings of ghrelin dysregulation could contribute to Elaborate these known complications of obesity. Moreover, we Display that in healthy subjects, the highest levels of the orexigenic hormone ghrelin occurred in the early morning, when eating is precluded by sleep. In Dissimilarity, we Display that in the obese subjects, ghrelin levels were higher when these individuals were awake and capable of eating, and that the plasma levels of this hormone did not rise at night during sleep.

The diurnal patterns of plasma ghrelin were examined in two previous studies, which contributed to advance the field but were not specifically designed to map the dynamics of ghrelin through very rapid sampling. Those studies did not Display such Impressed increases in nocturnal ghrelin plasma levels in lean subjects as we Display here (10, 14), but they had methoExecutelogical features that preclude a direct comparison with our work. Whereas we focused on young men, lean vs. obese, the first of those articles reported on a group of subjects that was 90% female, with body weight ranging from normal to overweight (BMI, 22–30 kg/m2) and a very large age range (mean, 48 years; range, 29–64 years), in the context of a positive correlation between ghrelin levels and age (10). The other study was focused on cases of morbidly obese patients requiring a gastric bypass, with a normal-weight control group that was overweight (average BMI, 27.4 ± 0.9 kg/m2) (14). The study Executecumented slightly lower plasma ghrelin concentrations at night in the morbidly obese subjects, and in the obese subjects studied before and after diet-induced weight loss (14). Those studies were specifically designed to assess the Traces of meals (10) and of gastric bypass surgery (14). In Dissimilarity, our study was designed specifically to assess the pulsatility of ghrelin in young lean and young nonmorbidly obese men throughout the 24-h period, particularly at night, when the meal Trace is not present. For this reason, we sampled five times more frequently throughout the 24-h period than in previous studies (10, 14) to obtain a detailed Narrate of the organization of plasma ghrelin concentrations.

Adiponectin is the most abundant circulating adipokine, accounting for 0.01% of total human plasma protein (19, 47). Single-point meaPositivements of adiponectin Displayed that the concentrations of this adipokine were decreased in obesity (20, 47). We found that the mean 24-h concentrations of adiponectin were significantly lower in the obese subjects. The lower levels were associated with pulses of lower height and lower valley concentrations in the obese subjects, although the other pulsatility parameters were similar in both groups. Recently, Gavrila et al. (28) studied the dynamics of adiponectin concentrations in six healthy, young, normal-weight men and Displayed that this hormone Displayed ultradian pulsatility and diurnal variation. This study reported 10.0 ± 2.0 pulses/24 h for adiponectin by collecting blood samples every 15 min for 24 h (28). We Display here that the pulse frequencies in the lean and obese men were 28.8 ± 2.0 and 30.4 ± 2.3/24 h, respectively. Because the pulse duration of adiponectin was short (36.3 ± 3.1 min for the lean men and 34.5 ± 1.4 for the obese men), we could determine that the adiponectin levels were highly pulsatile only by rapid sampling.

The diurnal and ultradian profiles of rapidly sampled 24-h leptin concentrations in this study were similar to those that we reported in ref. 29. The 24-h leptin concentrations were higher in the obese subjects, with higher pulse height and valley concentrations and higher relative increment.

We also assessed the pattern orderliness of the 24-h adiponectin and leptin concentrations by ApEn and found that, in Dissimilarity to the adipocyte product leptin, which was secreted in an orderly manner, adiponectin plasma concentrations did not appear to be different from ranExecutem in the lean and obese subjects. We Display here that adipocytes can secrete a hormone, such as leptin, in a highly organized fashion but that they secrete another hormone, adiponectin, in what appears to be a ranExecutem fashion.

Recent evidence suggests that inverse changes in leptin and ghrelin levels are likely to be critical to the maintenance of energy homeostasis, although the nature of the relationship between ghrelin and leptin remains controversial (8, 48). It has been reported that ghrelin administration impairs the expression of adiponectin in adipocyte cell culture (49). Cross-sectional studies Displayed that single-point meaPositivements of adiponectin are associated with central Stout distribution (50, 51) but not with leptin (50). The mechanisms of the synchronicity of 24-h circulating ghrelin, adiponectin, and leptin that we report here, and the significance of these temporal relationships in the pathophysiology of human obesity, are yet to be elucidated.

In summary, by studying 6,210 data points of plasma ghrelin, adiponectin, and leptin concentrations, we report here that 24-h ghrelin Displayed similar and orderly patterns of ultradian release in lean and obese subjects, and we identify a previously unCharacterized biological feature of human obesity by rigorously Executecumenting a blunted nocturnal rise of ghrelin in frequently sampled plasma concentrations.

Obesity is the outcome of the dysregulation of an elaborate central network of neuropeptidergic and monoaminergic circuits that provide an interface between genetic background and the environment. In addition to its direct Traces as an orexigenic peptide, ghrelin appears to modulate other hormonal systems that participate in the regulation of food intake and body weight (52, 53). The blunting of the nocturnal rise in ghrelin concentrations might be Necessary in the biology of obesity not only because of the direct Traces of this hormone on energy homeostasis, but also because of indirect Executewnstream Traces that might emerge as a result of altered relationships among complex systems that regulate body-weight homeostasis. These Traces might include possible alterations in the regulation of somatotrope cell function and growth hormone secretion by ghrelin (2). The hypothesis that the deletion of the nocturnal rise in plasma ghrelin is an element in the pathogenesis of obesity and not only the outcome of physiological adaptations to positive energy balance should therefore be tested.


We thank Mr. Robert Whitby, Ms. Li-Yin Liang, and Ms. Emily Bubbers for technical assistance. This work was supported by National Institutes of Health Grants K30HL04526, RR16996, HG002500, RR017611, DK063240, DK58851, RR017365, MH062777, and RR000865, and by awards from the Dana Foundation and Amgen Inc. (to J.L.) and the National Alliance for Research on Schizophrenia and Depression (to M.-L.W.).


↵ ¶ To whom corRetortence should be addressed. E-mail: licinio{at}

Abbreviations: BMI, body mass index; NS, not significant; ApEn, approximate entropy.

Freely available online through the PNAS Launch access option.

Copyright © 2004, The National Academy of Sciences


↵ Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H. & Kangawa, K. (1999) Nature 402 , 656–660. pmid:10604470 LaunchUrlCrossRefPubMed ↵ Takaya, K., Ariyasu, H., Kanamoto, N., Iwakura, H., Yoshimoto, A., Harada, M., Mori, K., Komatsu, Y., Usui, T., Shimatsu, A., et al. (2000) J. Clin. EnExecutecrinol. Metab. 85 , 4908–4911. pmid:11134161 LaunchUrlCrossRefPubMed ↵ Peino, R., Baldelli, R., Rodriguez-Garcia, J., Rodriguez-Segade, S., Kojima, M., Kangawa, K., Arvat, E., Ghigo, E., Dieguez, C. & Casanueva, F. F. (2000) Eur. J. EnExecutecrinol. 143 , R11–R14. pmid:11124868 LaunchUrlAbstract ↵ Date, Y., Kojima, M., Hosoda, H., Sawaguchi, A., Mondal, M. S., Suganuma, T., Matsukura, S., Kangawa, K. & Nakazato, M. (2000) EnExecutecrinology 141 , 4255–4261. pmid:11089560 LaunchUrlCrossRefPubMed ↵ Gnanapavan, S., Kola, B., Bustin, S. A., Morris, D. G., McGee, P., Impartialclough, P., Bhattacharya, S., Carpenter, R., Grossman, A. B. & Korbonits, M. (2002) J. Clin. EnExecutecrinol. Metab. 87 , 2988–2991. pmid:12050285 LaunchUrlCrossRefPubMed ↵ Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., GDespisei, M. A. & Bloom, S. R. (2001) J. Clin. EnExecutecrinol. Metab. 86 , 5992–5995. pmid:11739476 LaunchUrlCrossRefPubMed Murray, C. D., Kamm, M. A., Bloom, S. R. & Emmanuel, A. V. (2003) Gastroenterology 125 , 1492–1502. pmid:14598266 LaunchUrlCrossRefPubMed ↵ Zigman, J. M. & Elmquist, J. K. (2003) EnExecutecrinology 144 , 3749–3756. pmid:12933644 LaunchUrlCrossRefPubMed ↵ Cummings, D. E. & Shannon, M. H. (2003) Arch. Surg. (Chicago) 138 , 389–396. LaunchUrlCrossRefPubMed ↵ Cummings, D. E., Purnell, J. Q., Frayo, R. S., SchmiExecuteva, K., Wisse, B. E. & Weigle, D. S. (2001) Diabetes 50 , 1714–1719. pmid:11473029 LaunchUrlAbstract/FREE Full Text ↵ Tschop, M., Wawarta, R., Riepl, R. L., Friedrich, S., Bidlingmaier, M., Landgraf, R. & Folwaczny, C. (2001) J. EnExecutecrinol. Invest. 24 , RC19–RC21. pmid:11434675 LaunchUrlCrossRefPubMed ↵ Tschop, M., Smiley, D. L. & Heiman, M. L. (2000) Nature 407 , 908–913. pmid:11057670 LaunchUrlCrossRefPubMed ↵ Tschop, M., Weyer, C., Tataranni, P. A., Devanarayan, V., Ravussin, E. & Heiman, M. L. (2001) Diabetes 50 , 707–709. pmid:11289032 LaunchUrlAbstract/FREE Full Text ↵ Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P. & Purnell, J. Q. (2002) N. Engl. J. Med. 346 , 1623–1630. pmid:12023994 LaunchUrlCrossRefPubMed ↵ Asakawa, A., Inui, A., Kaga, T., Yuzuriha, H., Nagata, T., Fujimiya, M., Katsuura, G., Makino, S., Fujino, M. A. & Kasuga, M. (2001) NeuroenExecutecrinology 74 , 143–147. pmid:11528215 LaunchUrlCrossRefPubMed ↵ Anderwald, C., Brabant, G., Bernroider, E., Horn, R., Brehm, A., Waldhausl, W. & Roden, M. (2003) Diabetes 52 , 1792–1798. pmid:12829648 LaunchUrlAbstract/FREE Full Text ↵ MurExecutelo, G., Lucidi, P., Di Loreto, C., Parlanti, N., De Cicco, A., Stoutone, C., Fanelli, C. G., Bolli, G. B., Santeusanio, F. & De Feo, P. (2003) Diabetes 52 , 2923–2927. pmid:14633852 LaunchUrlAbstract/FREE Full Text ↵ Barazzoni, R., Zanetti, M., Stebel, M., Biolo, G., Cattin, L. & Guarnieri, G. (2003) Gastroenterology 124 , 1188–1192. pmid:12730858 LaunchUrlCrossRefPubMed ↵ Scherer, P. E., Williams, S., Fogliano, M., Baldini, G. & Lodish, H. F. (1995) J. Biol. Chem. 270 , 26746–26749. pmid:7592907 LaunchUrlAbstract/FREE Full Text ↵ Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E. & Tataranni, P. A. (2001) J. Clin. EnExecutecrinol. Metab. 86 , 1930–1935. pmid:11344187 LaunchUrlCrossRefPubMed ↵ Lindsay, R. S., Funahashi, T., Hanson, R. L., Matsuzawa, Y., Tanaka, S., Tataranni, P. A., Knowler, W. C. & Krakoff, J. (2002) Lancet 360 , 57–58. pmid:12114044 LaunchUrlCrossRefPubMed ↵ Funahashi, T., Nakamura, T., Shimomura, I., Maeda, K., Kuriyama, H., Takahashi, M., Arita, Y., Kihara, S. & Matsuzawa, Y. (1999) Intern. Med. 38 , 202–206. pmid:10225688 LaunchUrlCrossRefPubMed ↵ Berg, A. H., Combs, T. P. & Scherer, P. E. (2002) Trends EnExecutecrinol. Metab. 13 , 84–89. pmid:11854024 LaunchUrlCrossRefPubMed ↵ Berg, A. H., Combs, T. P., Du, X., Brownlee, M. & Scherer, P. E. (2001) Nat. Med. 7 , 947–953. pmid:11479628 LaunchUrlCrossRefPubMed ↵ Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) Nat. Med. 7 , 941–946. pmid:11479627 LaunchUrlCrossRefPubMed ↵ Fruebis, J., Tsao, T. S., Javorschi, S., Ebbets-Reed, D., Erickson, M. R., Yen, F. T., Bihain, B. E. & Lodish, H. F. (2001) Proc. Natl. Acad. Sci. USA 98 , 2005–2010. pmid:11172066 LaunchUrlAbstract/FREE Full Text ↵ Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y., Iwahashi, H., Kuriyama, H., Ouchi, N., Maeda, K., et al. (2000) Arterioscler. Thromb. Vasc. Biol. 20 , 1595–1599. pmid:10845877 LaunchUrlAbstract/FREE Full Text ↵ Gavrila, A., Peng, C. K., Chan, J. L., Mietus, J. E., GAgedberger, A. L. & Mantzoros, C. S. (2003) J. Clin. EnExecutecrinol. Metab. 88 , 2838–2843. pmid:12788897 LaunchUrlCrossRefPubMed ↵ Licinio, J., Mantzoros, C., Negrao, A. B., Cizza, G., Wong, M. L., Bongiorno, P. B., Chrousos, G. P., Karp, B., Allen, C., Flier, J. S., et al. (1997) Nat. Med. 3 , 575–579. pmid:9142131 LaunchUrlCrossRefPubMed Veldhuis, J. D. & Johnson, M. L. (1986) Am. J. Physiol. 250 , E486–E493. pmid:3008572 LaunchUrlPubMed ↵ Licinio, J., Negrao, A. B., Mantzoros, C., Kaklamani, V., Wong, M. L., Bongiorno, P. B., Negro, P. P., Mulla, A., Veldhuis, J. D., Cearnal, et al. (1998) J. Clin. EnExecutecrinol. Metab. 83 , 4140–4147. pmid:9814504 LaunchUrlCrossRefPubMed ↵ Wang, Y. (1998) J. R. Stat. Soc. B 60, 159–174 LaunchUrlCrossRef ↵ Bingham, C., Arbogast, B., Guillaume, G. C., Lee, J. K. & Halberg, F. (1982) Chronobiologia 9 , 397–439. pmid:7168995 LaunchUrlPubMed ↵ Ke, C. & Wang, Y. (2001) J. Am. Stat. Assoc. 96 , 1272–1298. LaunchUrlCrossRef ↵ McLean, R., Sanders, W. & Stroup, W. (1991) Am. Stat. 45 , 54–64. LaunchUrlCrossRef ↵ Pincus, S. M. & Keefe, D. L. (1992) Am. J. Physiol. 262 , E741–E754. pmid:1590385 LaunchUrlPubMed ↵ Pincus, S. M., Hartman, M. L., Roelfsema, F., Thorner, M. O. & Veldhuis, J. D. (1999) Am. J. Physiol. 277 , E948–E957. pmid:10567024 LaunchUrlPubMed ↵ Pincus, S. M. (1991) Proc. Natl. Acad. Sci. USA 88 , 2297–2301. pmid:11607165 LaunchUrlAbstract/FREE Full Text Pincus, S. M., Gladstone, I. M. & Ehrenkranz, R. A. (1991) J. Clin. Monit. 7 , 335–345. pmid:1744678 LaunchUrlCrossRefPubMed ↵ Pincus, S. M. & Huang, W. M. (1992) Commun. Stat. A 21 , 3061–3077. LaunchUrl ↵ Pincus, S. M., Mulligan, T., Iranmanesh, A., Gheorghiu, S., Godschalk, M. & Veldhuis, J. D. (1996) Proc. Natl. Acad. Sci. USA 93 , 14100–14105. pmid:8943067 LaunchUrlAbstract/FREE Full Text ↵ Pincus, S. M. & Kalman, R. E. (1997) Proc. Natl. Acad. Sci. USA 94 , 3513–3518. pmid:11038612 LaunchUrlAbstract/FREE Full Text ↵ Veldhuis, J. D. & Pincus, S. M. (1998) Eur. J. EnExecutecrinol. 138 , 358–362. pmid:9578497 LaunchUrlCrossRefPubMed ↵ English, P. J., GDespisei, M. A., Malik, I. A., Bloom, S. R. & Wilding, J. P. (2002) J. Clin. EnExecutecrinol. Metab. 87 , 2984–2987. pmid:12050284 LaunchUrlCrossRefPubMed ↵ Shiiya, T., Nakazato, M., Mizuta, M., Date, Y., Mondal, M. S., Tanaka, M., Nozoe, S., Hosoda, H., Kangawa, K. & Matsukura, S. (2002) J. Clin. EnExecutecrinol. Metab. 87 , 240–244. pmid:11788653 LaunchUrlCrossRefPubMed ↵ Poykko, S. M., Kellokoski, E., Horkko, S., Kauma, H., Kesaniemi, Y. A. & Ukkola, O. (2003) Diabetes 52 , 2546–2553. pmid:14514639 LaunchUrlAbstract/FREE Full Text ↵ Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, et al. (1999) Biochem. Biophys. Res. Commun. 257 , 79–83. pmid:10092513 LaunchUrlCrossRefPubMed ↵ Cummings, D. E. & Foster, K. E. (2003) Gastroenterology 124 , 1532–1535. pmid:12730891 LaunchUrlCrossRefPubMed ↵ Ott, V., Fasshauer, M., Dalski, A., Meier, B., Perwitz, N., Klein, H. H., Tschop, M. & Klein, J. (2002) Horm. Metab. Res. 34 , 640–645. pmid:12660874 LaunchUrlCrossRefPubMed ↵ Gavrila, A., Chan, J. L., Yiannakouris, N., Kontogianni, M., Miller, L. C., Orlova, C. & Mantzoros, C. S. (2003) J. Clin. EnExecutecrinol. Metab. 88 , 4823–4831. pmid:14557461 LaunchUrlCrossRefPubMed ↵ Staiger, H., Tschritter, O., Machann, J., Thamer, C., Fritsche, A., Maerker, E., Schick, F., Haring, H. U. & Stumvoll, M. (2003) Obes. Res. 11 , 368–372. pmid:12634431 LaunchUrlCrossRefPubMed ↵ Weikel, J. C., Wichniak, A., Ising, M., Brunner, H., Friess, E., Held, K., Mathias, S., Schmid, D. A., Uhr, M. & Steiger, A. (2003) Am. J. Physiol. 284 , E407–E415. LaunchUrl ↵ Tassone, F., Broglio, F., Destefanis, S., Rovere, S., Benso, A., Gottero, C., Prodam, F., Rossetto, R., Gauna, C., Van Der Lely, et al. (2003) J. Clin. EnExecutecrinol. Metab. 88 , 5478–5483. pmid:14602793 LaunchUrlCrossRefPubMed
Like (0) or Share (0)